ABSTRACT RNA interference (RNAi) is an ancient biological mechanism used to defend
against external invasion. It theoretically can silence any disease-related genes in a …

The RNA interference (RNAi) pathway regulates mRNA stability and translation in nearly all
human cells. Small double-stranded RNA molecules can efficiently trigger RNAi silencing of …

Messenger RNA (mRNA)-based therapeutics hold the potential to cause a major revolution
in the pharmaceutical industry because they can be used for precise and individualized …

The European Medicines Agency (EMA) and the Current Good Manufacturing Practices
(cGMP) in the United States of America, define excipient as the constituents of the …

Efficient viral or nonviral delivery of nucleic acids is the key step of genetic nanomedicine.
Both viral and synthetic vectors have been successfully employed for genetic delivery with …

Abstract Recently, United States Food and Drug Administration (FDA) and European
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …

Drug resistance and toxicity constitute challenging hurdles for cancer therapy. The
application of nanotechnology for anticancer drug delivery is expected to address these …

Conspectus Delivery remains a major obstacle restricting the potential action of small
molecular drugs as well as novel biologics which cannot readily enter cells without the help …

Drug delivery systems (DDSs) that can overcome tumor heterogeneity and achieve deep
tumor penetration are challenging to develop yet in high demand for cancer treatment. We …

Small interfering RNA (siRNA) is emerging as a novel therapeutic for treating various
diseases, provided a safe and efficient delivery is available. In particular, specific delivery to …